exRNAdisease

Entry Detail

---



General Information

Database ID: exR0087931 RNA Name: hsa-miR-217-5p RNA Type: miRNA Chromosome: chr2 Starnd: - Coordinate: Start Site(bp): 55983020 End Site(bp): 55983042 External Links: hsa-miR-217-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE101841 Description: Serum microRNA profile of Her2 positive metastatic breast cancer patients Experimental Design: Trastuzumab therapy Case Disease Type: Breast Cancer Case Disease SubType: HER2 positive metastatic breast cancer Case Sample: Breast Cancer Trastuzumab resistant Control Sample: Trastuzumab sensitive Number of Case: 42 Number of Control: 61 Number of Samples: 103

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand PNPO chr17 47941506 47949308 + SLC26A2 chr5 149960758 149993455 + ICAM1 chr19 10271093 10286615 + ARHGAP11A chr15 32615144 32639941 + SFXN1 chr5 175477062 175529742 + EIF1AD chr11 65996545 66002176 - KPNA4 chr3 160495007 160565571 - LYSMD4 chr15 99715697 99733561 - AXL chr19 41219223 41261766 + OPA3 chr19 45527427 45602212 - IRF4 chr6 391752 411443 + SLC25A32 chr8 103398635 103415189 - UBE2G1 chr17 4269259 4366628 - MMD chr17 55392622 55421924 - CDH1 chr16 68737292 68835541 + ICK chr6 53001279 53061802 - PARD6B chr20 50731580 50756795 + GOLGA3 chr12 132768914 132829078 - MET chr7 116672196 116798386 + ACER2 chr9 19409009 19452505 + PSKH1 chr16 67893254 67929676 + EIF2S3 chrX 24054946 24078810 + VHL chr3 10141008 10152220 + DDX3X chrX 41333284 41364472 + ZNF587 chr19 57849859 57865117 + TSEN54 chr17 75516060 75524735 + CNN2 chr19 1026586 1039068 + CHD9 chr16 53055033 53329150 + ERLIN1 chr10 100150094 100186033 - TFPI chr2 187464230 187565760 - miRNA targets: NA circRNA targets: NA lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand ADAMTSL4-AS1 chr1 150560202 150574552 - AP000553.1 chr22 21652270 21670237 + GAS5 chr1 173858559 173868882 - LINC01578 chr15 92819540 92899701 + MALAT1 chr11 65497688 65506516 + NEAT1 chr11 65422774 65445540 + OIP5-AS1 chr15 41283990 41309737 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE101841 Sample Source: Blood Source Fraction: Serum Platform: GPL23138 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 1808 Sample treatment protocol: NA RNA Extract protocol: Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions. RNA library preparation protocol: Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID: 29691399 Title: A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Author: Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E Journal: Nat Commun. 2018 Apr 24;9(1):1614. Description: MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.